Xenopat

Xenopat is a private Spanish oncology-focused CRO and biotech services company that develops and applies advanced in vivo cancer models to support anticancer drug development and personalized treatment selection. The company specializes in Orthoxenograft® patient-derived orthotopic xenograft models, alongside broader preclinical oncology capabilities including PDX, humanized murine, cell-derived xenograft, and syngeneic models. Xenopat offers researchers and biopharma customers model generation, efficacy testing, and translational decision support across preclinical, co-clinical, and clinical settings. The company also maintains OrthoXenoBank®, a bank of genetically and histologically characterized tumor models spanning multiple cancer types. Xenopat appears to operate primarily as a services and platform business rather than as a developer of its own therapeutic pipeline.